DJIA 16,912.11 -70.48 -0.42%
NASDAQ 4,442.70 -2.21 -0.05%
S&P 500 1,969.95 -8.96 -0.45%
market minute promo

Durata Therapeutics (NASDAQ: DRTX)

12.80 -0.55 (-4.12%)

REAL-TIME: Last trade at

Extended Hours: $12.55 -$0.25 (-1.95%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

DRTX $12.80 -4.12%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.17
Previous Close $13.35
Daily Range $12.50 - $13.20
52-Week Range $7.73 - $18.17
Market Cap $341.0M
P/E Ratio -5.43
Dividend (Yield) $0.00 (0.0%)
Volume 522,421
Average Daily Volume 260,077
Current FY EPS -$2.74

Sector

Healthcare

Industry

Drugs

Durata Therapeutics (DRTX) Description

Durata Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Website: http://www.duratatherapeutics.com/

News & Commentary

3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata

A video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.

Durata Therapeutics Announces US Launch of Dalvance

Commit To Buy Durata Therapeutics At $15, Earn 24.6% Annualized Using Options

Cubist Gains FDA Approval for Sivextro - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog

Orexigen Will Run: Here's Why

Sector Update: Healthcare Stocks Higher Pre-Market; Durata Sinks 11% After Strong Rally

Sector Update: Healthcare

Benzinga's Top #PreMarket Losers

Stocks To Watch For May 27, 2014

Durata Confirms FDA Approval of DALVANCE for Skin Infections

See More DRTX News...